Household Income Is Associated with the p53 Mutation Frequency in Human Breast Tumors

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Starks, Adrienne M ^a   Martin, Damali N ^a   Dorsey, Tiffany H ^a   Boersma, Brenda J ^a   Wallace, Tiffany A ^a   Ambs, Stefan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN P53;

ADULT; AFRICAN AMERICAN; AGE; AGED; ARTICLE; BODY MASS; BREAST CANCER; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; EDUCATION; ETHNICITY; EUROPEAN AMERICAN; HOUSEHOLD; HUMAN; HUMAN CELL; HUMAN TISSUE; INCOME; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; P53 GENE; RACE; SELF REPORT; SMOKING; SOCIOECONOMICS; UNITED STATES;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; BALTIMORE; BODY MASS INDEX; BREAST NEOPLASMS; EDUCATIONAL STATUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCOME; MIDDLE AGED; MUTATION RATE; RECEPTORS, ESTROGEN; REGRESSION ANALYSIS; RISK FACTORS; SMOKING; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874565741     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057361     Document Type: Article

References (50)

1. Kamangar F, Dores GM, Anderson WF, (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150.
2. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, et al. (2011) Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 378: 1461-1484.
3. Desantis C, Siegel R, Bandi P, Jemal A, (2011) Breast cancer statistics, 2011. CA Cancer J Clin 61: 409-418.
4. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, et al. (2005) Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97: 439-448.
5. Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D, (2005) Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 294: 1765-1772.
6. Hershman D, McBride R, Jacobson JS, Lamerato L, Roberts K, et al. (2005) Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol 23: 6639-6646.
7. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502.
8. Curtis E, Quale C, Haggstrom D, Smith-Bindman R, (2008) Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer 112: 171-180.
9. van Ravesteyn NT, Schechter CB, Near AM, Heijnsdijk EA, Stoto MA, et al. (2011) Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States. Cancer Epidemiol Biomarkers Prev 20: 112-122.
10. Wallace TA, Martin DN, Ambs S, (2011) Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis 32: 1107-1121.
11. Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, et al. (2006) Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol 24: 1342-1349.
12. Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL, (2009) Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 101: 984-992.
13. Gordon NH, (1995) Association of education and income with estrogen receptor status in primary breast cancer. Am J Epidemiol 142: 796-803.
14. Thomson CS, Hole DJ, Twelves CJ, Brewster DH, Black RJ, (2001) Prognostic factors in women with breast cancer: distribution by socioeconomic status and effect on differences in survival. J Epidemiol Community Health 55: 308-315.
15. Jones BA, Kasl SV, Howe CL, Lachman M, Dubrow R, et al. (2004) African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer 101: 1293-1301.
16. Martin DN, Boersma BJ, Yi M, Reimers M, Howe TM, et al. (2009) Differences in the Tumor Microenvironment between African-American and European-American Breast Cancer Patients. PLoS ONE 4: e4531.
17. Greenblatt MS, Bennett WP, Hollstein M, Harris CC, (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878.
18. Baker L, Quinlan PR, Patten N, Ashfield A, Birse-Stewart-Bell LJ, et al. (2010) p53 mutation, deprivation and poor prognosis in primary breast cancer. Br J Cancer 102: 719-726.
19. Pharoah PD, Day NE, Caldas C, (1999) Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 80: 1968-1973.
20. Soussi T, Beroud C, (2001) Assessing TP53 status in human tumours to evaluate clinical outcome. Nature Rev Cancer 1: 233-240.
21. Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, et al. (2006) Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 98: 911-919.
22. Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, et al. (2009) Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 11: R18.
23. Thor AD, Moore DHII, Edgerton SM, Kawasaki ES, Reihsaus E, et al. (1992) Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84: 845-855.
24. Sasa M, Kondo K, Komaki K, Morimoto T, Monden Y, (1994) p53 alteration correlates with negative ER, negative PgR, and high histologic grade in breast cancer. J Surg Oncol 56: 46-50.
25. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, et al. (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811-814.
26. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, et al. (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12: 1157-1167.
27. Hussain SP, Harris CC, (1999) p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat Res 428: 23-32.
28. Calza S, Hall P, Auer G, Bjohle J, Klaar S, et al. (2006) Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 8: R34.
29. The Human Cancer Genome Network, (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
30. Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, et al. (2002) Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 87: 1234-1245.
31. Narod SA, (2011) Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol 8: 669-676.
32. Bernstein L, Teal CR, Joslyn S, Wilson J, (2003) Ethnicity-related variation in breast cancer risk factors. Cancer 97: 222-229.
33. Freudenheim JL, Bonner M, Krishnan S, Ambrosone CB, Graham S, et al. (2004) Diet and alcohol consumption in relation to p53 mutations in breast tumors. Carcinogenesis 25: 931-939.
34. Fernandez SV, Russo IH, Russo J, (2006) Estradiol and its metabolites 4-hydroxyestradiol and 2-hydroxyestradiol induce mutations in human breast epithelial cells. Int J Cancer 118: 1862-1868.
35. Miller GE, Chen E, Fok AK, Walker H, Lim A, et al. (2009) Low early-life social class leaves a biological residue manifested by decreased glucocorticoid and increased proinflammatory signaling. Proc Natl Acad Sci U S A 106: 14716-14721.
36. Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Oser SM, et al. (1999) Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst 91: 86-88.
37. Vaninetti NM, Geldenhuys L, Porter GA, Risch H, Hainaut P, et al. (2008) Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Mol Carcinog 47: 275-285.
38. Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, et al. (2010) Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest 120: 3843-3854.
39. Igarashi H, Hashimoto J, Tomita T, Yoshikawa H, Ishihara K, (2010) TP53 mutations coincide with the ectopic expression of activation-induced cytidine deaminase in the fibroblast-like synoviocytes derived from a fraction of patients with rheumatoid arthritis. Clin Exp Immunol 161: 71-80.
40. Hermes GL, Delgado B, Tretiakova M, Cavigelli SA, Krausz T, et al. (2009) Social isolation dysregulates endocrine and behavioral stress while increasing malignant burden of spontaneous mammary tumors. Proc Natl Acad Sci U S A 106: 22393-22398.
41. Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, et al. (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70: 7042-7052.
42. Pan D, Kocherginsky M, Conzen SD, (2011) Activation of the Glucocorticoid Receptor Is Associated with Poor Prognosis in Estrogen Receptor-Negative Breast Cancer. Cancer Res 71: 6360-70.
43. Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE, et al. (2006) The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer 6: 240-248.
44. Miller GE, Chen E, Parker KJ, (2011) Psychological stress in childhood and susceptibility to the chronic diseases of aging: moving toward a model of behavioral and biological mechanisms. Psychol Bull 137: 959-997.
45. Glynn SA, Prueitt RL, Ridnour LA, Boersma BJ, Dorsey TM, et al. (2010) COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer. BMC Cancer 10: 626.
46. Piao CQ, Willey JC, Hei TK, (1999) Alterations of p53 in tumorigenic human bronchial epithelial cells correlate with metastatic potential. Carcinogenesis 20: 1529-1533.
47. Colomer A, Erill N, Verdu M, Roman R, Vidal A, et al. (2003) Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas. Appl Immunohistochem Mol Morphol 11: 130-137.
48. Coombs NJ, Gough AC, Primrose JN, (1999) Optimisation of DNA and RNA extraction from archival formalin-fixed tissue. Nucleic Acids Res 27: e12.
49. Ahrendt SA, Halachmi S, Chow JT, Wu L, Halachmi N, et al. (1999) Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci U S A 96: 7382-7387.
50. Ahrendt SA, Hu Y, Buta M, McDermott MP, Benoit N, et al. (2003) p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst 95: 961-970.